840-12 - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey

840-12 - Rutgers Cancer Institute of New Jersey is a clinical research site located in New Brunswick, New Jersey, United States 08903.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

840-12 - Rutgers Cancer Institute of New Jersey has participated in 1 clinical trials.

Therapeutic areas: Colo-rectal Cancer.

Sponsors: Isofol Medical AB.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for 840-12 - Rutgers Cancer Institute of New Jersey?

840-12 - Rutgers Cancer Institute of New Jersey has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has 840-12 - Rutgers Cancer Institute of New Jersey conducted?

840-12 - Rutgers Cancer Institute of New Jersey has 1 clinical trials on record. Their work covers Colo-rectal Cancer.

Is 840-12 - Rutgers Cancer Institute of New Jersey accredited by Crixeo Health?

840-12 - Rutgers Cancer Institute of New Jersey has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about 840-12 - Rutgers Cancer Institute of New Jersey?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.